BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for FIVE PRIME THERAPEUTICS INC:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-03-08 4:54 pm Purchase |
2021-03-04 | 13G | FIVE PRIME THERAPEUTICS INC FPRX |
BIOTECHNOLOGY VALUE FUND L P | 6,338,678 13.800% |
3,200,000 (+101.95%) |
Filing |
| 2021-02-01 5:19 pm Purchase |
2021-01-22 | 13G | FIVE PRIME THERAPEUTICS INC FPRX |
BIOTECHNOLOGY VALUE FUND L P | 3,138,678 7.200% |
1,875,000 (+148.38%) |
Filing |
| 2020-11-13 5:27 pm Sale |
2020-11-11 | 13D | FIVE PRIME THERAPEUTICS INC FPRX |
BIOTECHNOLOGY VALUE FUND L P | 1,263,678 3.300% |
-7,100,675 (-84.89%) |
Filing |
| 2020-10-08 5:26 pm Purchase |
2020-10-06 | 13D | FIVE PRIME THERAPEUTICS INC FPRX |
BIOTECHNOLOGY VALUE FUND L P | 8,364,353 22.800% |
581,352 (+7.47%) |
Filing |